Skip to Main Content
Table 2

Immunohistochemical analysis of human pancreatic carcinoma in the pancreas of control and treated nude mice

Treatment groupaTumor cellsEndothelial cells
PCNA+TUNEL+VEGFIL-8CD31+% TUNEL+
Control 594 ± 47b 13 ± 6b 265 ± 21c 235 ± 7c 82 ± 25b 1.6d 
Gemcitabine 353 ± 18 47 ± 13e 245 ± 35 165 ± 7e 65 ± 1 2.6 
PKI 166, 3 days/wk 165 ± 4e 71 ± 8f 180 ± 10e 175 ± 7e 37 ± 4e 20e 
PKI 166, 7 days/wk 95 ± 25e 100 ± 20f 145 ± 7e 170 ± 14e 29 ± 6e 22e 
PKI 166, 3 days/wk + gemcitabine 84 ± 14e 85 ± 13f 143 ± 15e 160 ± 14e 9 ± 3f 27f 
PKI 166, 7 days/wk + gemcitabine 85 ± 13e 127 ± 17f 124 ± 28e 155 ± 7e 8 ± 1f 30f 
Treatment groupaTumor cellsEndothelial cells
PCNA+TUNEL+VEGFIL-8CD31+% TUNEL+
Control 594 ± 47b 13 ± 6b 265 ± 21c 235 ± 7c 82 ± 25b 1.6d 
Gemcitabine 353 ± 18 47 ± 13e 245 ± 35 165 ± 7e 65 ± 1 2.6 
PKI 166, 3 days/wk 165 ± 4e 71 ± 8f 180 ± 10e 175 ± 7e 37 ± 4e 20e 
PKI 166, 7 days/wk 95 ± 25e 100 ± 20f 145 ± 7e 170 ± 14e 29 ± 6e 22e 
PKI 166, 3 days/wk + gemcitabine 84 ± 14e 85 ± 13f 143 ± 15e 160 ± 14e 9 ± 3f 27f 
PKI 166, 7 days/wk + gemcitabine 85 ± 13e 127 ± 17f 124 ± 28e 155 ± 7e 8 ± 1f 30f 
a

L3.6pl human pancreatic cancer cells (1 × 106) were injected into the pancreas of nude mice. Seven days later, groups of mice were treated with biweekly i.p. injections of gemcitabine (125 mg/kg) alone, daily (3 or 7 days a week) oral feedings of PKI 166 (50 mg/kg) alone, PKI 166 in combination with gemcitabine, or saline (control). All mice were killed on day 35.

b

The number (mean ± SD) of positive cells/field determined from measurement of 10 random 0.159-mm2 fields at ×100 magnification.

c

Mean ± SD absorbance, determined as described in “Materials and Methods.”

d

The number (mean ± SD) of CD31/TUNEL-positive cells in 10 random 0.011-mm2 fields at ×400 magnification. Fluorescent double labeling was performed on frozen tissue sections.

e

P < 0.05 as compared with controls.

f

P < 0.001 as compared with controls.

Close Modal

or Create an Account

Close Modal
Close Modal